Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Evidence returned 38 record(s)
|
|
Sunday, 07/29/2018
|
Seeing the Big Picture in, and Having More Influence on, the Statistics Profession from Your Vantage Point
Amanda L. Golbeck, University of Arkansas for Medical Sciences
2:05 PM
|
Leading Toward Evidence-Based Educational Improvement Using the CBMS Survey
Ellen E. Kirkman, Wake Forest University
2:30 PM
|
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies
Shirley Wang
4:05 PM
|
The Strategy and Tactics of Search Advertising Business: Evidence from the Chinese E-Commerce Market
Min Li, California State University, Sacramento; Joseph Richards, California State University, Sacramento
4:20 PM
|
A Glimpse into Industry Experience with RWE to Transform Pharmaceutical Research and Development
James Harnett
4:25 PM
|
Real World Evidence Demonstration Projects and Policy Development at FDA
Diqiong Xie, FDA; David Barrett Martin, FDA CDER OMP
4:45 PM
|
Exploring the Dynamics of Interprovincial Mobility in China, Evidence from Panel Data
Xin Shi, Manchester Metropolitan University; James Cheng, Manchester Metropolitan University
5:35 PM
|
|
Monday, 07/30/2018
|
Challenges in Oncology: Pragmatic Trials Using Real-World Evidence
Zhe Zhang, Pfizer
|
The Discussion Statistical Methods on Meta-Analysis Are Including Parameters Estimation and Hypothesis Test in 2x2 Table
Jin-Hua Chen
|
Does Sexual Orientation and Gender Identity (SOGI) Question-Wording Influence Responses?: Evidence from an Experimental Test in a Non-Traditional Sample
Deirdre Middleton, --None--; Matt Jans, ICF; Naomi Freedner, ICF; Lee Harding, ICF; Ronaldo Iachan, ICF; Scott Worthge, MFour; James Dayton, ICF
|
Absence of Evidence Is Not Evidence of Absence: a Better Parallel Trends Test
Alyssa Bilinski, Harvard Graduate School of Arts and Sciences; Laura Hatfield, Harvard Medical School
|
The Role of Real World Evidence in a Regulatory Environment: Focus on Safety
Estelle Russek-Cohen, US FDA CDER
8:35 AM
|
Learning Individualized Treatment Rules from Electronic Health Records Data
Yuanjia Wang, Columbia University
9:00 AM
|
Linking Medicare Current Beneficiary Survey (MCBS) to Augment Post-Market Real World Data from Medicare Claims: a Multiple Imputation Approach
Yun Lu, FDA; Xiyuan Wu, Acumen LLC; Yoganand Chillarige, Acumen LLC; Michael Wernecke, Acumen LLC; Hector Izurieta, FDA; Jeffrey Kelman, CMS; Richard Forshee , FDA
9:20 AM
|
Visual Analytics in the Real World Evidence Data Realm
Melvin Munsaka, AbbVie, Inc.; Kefei Zhou, Theravance Biopharma; Krishan P. Singh, GlaxoSmithKline
9:35 AM
|
Absence of Evidence Is Not Evidence of Absence: a Better Parallel Trends Test
Alyssa Bilinski, Harvard Graduate School of Arts and Sciences; Laura Hatfield, Harvard Medical School
10:00 AM
|
Administrative Records for Survey Methodology and Evidence Building
Asaph Young Chun, US Census Bureau; Bruce Meyer, University of Chicago; Paul Biemer, RTI Internatinoal
10:35 AM
|
Use of Real-World Data and Real-World Evidence for Regulatory Decisions: Opportunities and Challenges
Lilly Yue, U.S. Food and Drug Administration; Nelson Lu, U.S. Food and Drug Administration; Yunling Xu, FDA/CDRH
10:35 AM
|
A Propensity Score Stratified Bayesian Power Prior Approach for Incorporating Real-World Evidence in Single Group Medical Device Clinical Studies
Chenguang Wang, John Hopkins University; Ram Tiwari, Center for Devices and Radiologica Health, FDA; Lilly Yue, U.S. Food and Drug Administration; Yunling Xu, FDA/CDRH
10:55 AM
|
Current Challenges in Linking Federal and State Data for Evidence-Building
Robert Goerge, Chapin Hall at the University of Chicago; Leah Gjertson, Chapin Hall at the University of Chicago
2:05 PM
|
Constructing Independent Evidence from Regression and Instrumental Variables with an Application to the Effect of Violent Conflict on Altruism and Risk Preference
Bikram Karmakar, University of Pennsylvania; Dylan Small, University of Pennsylvania
3:05 PM
|
|
Tuesday, 07/31/2018
|
Bayesian Methods in Real-World Evidence for Medicinal Product Development: Can Prior Distributions Provide a Platform for Creating Real-World Evidence?
John Loewy, Dataforethought
|
The Commission on Evidence-Based Policy Making - One Year Later
Katharine Abraham, University of Maryland; Nancy Potok, Office of Management and Budget; Amy O'Hara, Stanford University; Julia Lane, New York University
8:35 AM
|
A Bayesian Approach to the Analysis of Handwritten Evidence
Amy M Crawford, Iowa State University; Nicholas S Berry, Iowa State University; Alicia Carriquiry, Iowa State University
9:55 AM
|
Evidence-based Policy for People with Disabilities: An Analysis of Disabilities in the DPRK within the Global Context of Disability Studies
Giang Huong Nguyen, University of Iowa; Allison Conners, University of Toronto; Sophie Lee, ISR Foundation Center for Interdisciplinary Research; Nema Dean, University of Glasgow; Paul Chun, ISR Foundation Center for Interdisciplinary Research
2:05 PM
|
|
Wednesday, 08/01/2018
|
When Do We Really Need Randomized Clinical Trials?
Christopher Hane, OptumLabs; William Crown, OptumLabs
|
Collaborative Problem Solving Education in Global Perspective: The Evidence from PISA
Mack Shelley, Iowa State University; Senay Purzer, Purdue University
|
Collaborative Problem Solving Education in Global Perspective: The Evidence from PISA
Mack Shelley, Iowa State University; Senay Purzer, Purdue University
10:00 AM
|
What Constitutes Scientific Evidence - Controversies in Rare Disease Trial Designs and Personalized Medicine
Mark Chang, Veristat
10:35 AM
|
On Randomized Controlled Trials with Integrated Real World Evidence for Drug Development in Rare Diseases
Qing Liu, Amicus Therapeutics, Inc
11:15 AM
|
Evaluating Different Analytic Strategies to Translate Real World Data to Robust Evidence for Decision Making
Hongwei Wang, AbbVie Inc; Weili He, AbbVie; Yabing Mai, AbbVie, Inc; Meijing Wu, AbbVie; Dajun Tian, Chiltern
2:05 PM
|
Opportunities of Using Real World Data to Inform Regulatory Considerations for Medical Devices
Martin Ho, FDA
2:25 PM
|
Network Meta-Analysis for N-Of-1 Trials with Ordinal Outcomes
Youdan Wang, Brown University; Christopher Schmid, Brown University
3:05 PM
|
|
Thursday, 08/02/2018
|
Real World Data and Evidence in Health Care Decision Making
Kun Chen, AbbVie Inc; Weili He, AbbVie; Hongwei Wang, AbbVie Inc; Yabing Mai, AbbVie, Inc; Qiming Liao, AbbVie Inc
8:35 AM
|
Utilization of Historical Data and Real World Evidence in Clinical Trial Development - Case Studies in Rare Disease and Oncology
Florence H Yong, Pfizer Inc.; Ray Li, Pfizer Inc.; Steven Y Hua, Celgene - Receptos; Jeffery Palmer, Pfizer Inc.; Roberto Bugarini, Pfizer Inc.
8:50 AM
|
Bayesian Hierarchical Methods for Meta-Analysis Combining Randomized-Controlled and Single-Arm Studies
Jing Zhang, University of Maryland College Park; Chia-Wen Ko, U.S. Food and Drug Administration; Lei Nie, Division of Biometrics V, office of Biostatistics, CDER/FDA; Yong Chen, University of Pennsylvania; Ram Tiwari, Center for Devices and Radiologica Health, FDA
10:55 AM
|
Deriving and Analyzing Endpoints from Electronic Health Record Data: a Case Study from Clinical Oncology
Sandra Griffith, Flatiron Health; Ariel Bourla, Flatiron Health; Bryan Bowser, Flatiron Health ; Geoff Calkins, Flatiron Health; Joe Chang, Flatiron Health; Rebecca Miksad , Flatiron Health ; Brian Segal, Flatiron Health; Elizabeth Sweeney, Flatiron Health ; Erin Williams, Flatiron Health ; Paul You , Flatiron Health ; Amy Abernethy, Flatiron Health
11:15 AM
|
A Modified Two-Stage Approach to the Interpretation of Forensic Evidence
Cami M. Fuglsby, South Dakota State University; Christopher P. Saunders, South Dakota State University; Danica Ommen, Iowa State University; JoAnn Buscaglia, FBI Laboratory, Counterterrorism & Forensic Science Research Unit
11:20 AM
|
|
|
